This inventor holds 2 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignee: Otsuka Pharmaceutical Company, Limited. Active years: 2021-2024.
Company Filing History:
Years Active: 2021-2024
Title: Colin Thomas Lindley: Innovator in Pharmaceutical Compounds
Introduction
Colin Thomas Lindley is a notable inventor based in Stanford in the Vale, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative compounds. With a total of 2 patents to his name, Lindley continues to push the boundaries of medical science.
Latest Patents
Lindley's latest patents focus on a compound known as a 6-pyrimidin-isoindole derivative, which acts as an ERK1/2 inhibitor. This invention relates to the compound (2R)-2-(6-{5-chloro-2-[(oxan-4-yl)amino]pyrimidin-4-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)-N-[(1S)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]propanamide. The patent details novel physical forms of the compound, a process for preparing it, synthetic intermediates for use in the process, and novel formulations containing the compound, as well as its therapeutic uses.
Career Highlights
Colin Thomas Lindley is currently associated with Otsuka Pharmaceutical Company, Limited, where he applies his expertise in pharmaceutical innovation. His work has been instrumental in advancing the understanding and application of new therapeutic compounds.
Collaborations
Lindley has collaborated with esteemed colleagues such as Paul Anthony Baguley and Robert Craig Melling. These partnerships have fostered a collaborative environment that enhances the development of innovative solutions in the pharmaceutical industry.
Conclusion
Colin Thomas Lindley is a distinguished inventor whose work in pharmaceutical compounds has the potential to impact therapeutic practices significantly. His contributions continue to inspire advancements in medical science.